Sonalasense Inc
Publicly observedSan Carlos, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Carlos | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Sonalasense Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | LC3GHFGF2KK1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Apr 2023Publicly observed
NIH SBIR/STTR award: Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme
USD 497,384.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2023Publicly observed
NIH SBIR/STTR award: Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme
USD 796,215.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.